Hormone therapy impairs endothelial function in postmenopausal women with type 2 diabetes mellitus treated with rosiglitazone

The Journal of Clinical Endocrinology and Metabolism
Suzy Y HonisettPaul A Komesaroff

Abstract

Diabetes and ovarian senescence are associated with impaired endothelial function and altered arterial mechanical properties. Alterations in normal vascular structure and functioning are the primary cause of mortality and morbidity with type 2 diabetes. Similarly, after menopause, women experience an increase in the rate of cardiovascular disease. Thiazolidinediones have exhibited a number of antiatherogenic actions in populations with type 2 diabetes. The effect of thiazolidinediones in combination with hormone therapy (HT) in postmenopausal women is, however, unknown. To assess whether HT (transdermal estradiol 50 microg and micronized progesterone (100 mg/d) affects vascular function, 21 women receiving rosiglitazone were randomly assigned to receive HT or placebo for 12 wk in a double-blind crossover design. Measures of glycemic control, lipids, blood pressure, flow-mediated dilation, and distensibility index were undertaken at baseline and after each treatment. As a result, flow-mediated dilation was significantly reduced (15.3 +/- 3.8 to 6.6 +/- 1.6%, P = 0.02) with HT, whereas lipids, blood pressure, and distensibility index were unchanged. Placebo had no significant affect on any variables. Thus, the addition of HT to r...Continue Reading

References

Apr 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·E A HamF A Kuehl
Oct 1, 1992·British Journal of Obstetrics and Gynaecology·M FalkebornT Naessén
Sep 12, 1991·The New England Journal of Medicine·M J StampferC H Hennekens
Aug 1, 1994·European Journal of Endocrinology·J M FayardC Laugier
Jan 1, 1996·Obstetrics and Gynecology·B EttingerC P Quesenberry
Jan 15, 1999·Clinical and Experimental Pharmacology & Physiology·J Ludbrook
Feb 10, 2000·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research GroupDavid M Nathan
Feb 7, 2001·JAMA : the Journal of the American Medical Association·V FonsecaA Salzman
Mar 7, 2001·The Journal of Clinical Endocrinology and Metabolism·H E LebovitzUNKNOWN Rosiglitazone Clinical Trials Study Group
Mar 8, 2002·American Journal of Physiology. Endocrinology and Metabolism·Shanhong LingKrishnankutty Sudhir

❮ Previous
Next ❯

Citations

Sep 13, 2006·Current Hypertension Reports·Muhammad S Ashraf, Wanpen Vongpatanasin
Oct 22, 2005·Lancet Neurology·Cheryl D Bushnell
Aug 17, 2016·International Journal of Molecular Sciences·Veronika A MyasoedovaAlexander N Orekhov

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.